Nanoparticles designed to trap and neutralise large amounts of SARS-CoV2
Peer-Reviewed Publication
Updates every hour. Last Updated: 1-May-2025 11:08 ET (1-May-2025 15:08 GMT/UTC)
Researchers from the IBB-UAB have developed a new class of nanostructures capable of trapping and neutralising large quantities of the SARS-CoV2 virus particles, both in liquid solutions and on the surface of materials. These novel nanoparticles could be used to manufacture antiviral materials such as wastewater and air filters, and could be exploited to develop new tests for the early detection of Covid-19. Moreover, the nanoparticles could be redesigned to target other pathogens.
A new study led by Rutgers Health researchers has uncovered important insights into vaccination patterns among LGBTQ+ adults in New Jersey and New York. The findings, published in the journal Vaccine, shed light on disparities in vaccine uptake within this diverse population.
the study highlights that LTV is more effective than NTV and ETV against Mpro mutants, making it a promising candidate for treating drug-resistant strains of SARS-CoV-2.
A study conducted by researchers from the CUNY Graduate School of Public Health and Health Policy (CUNY SPH) and the Barcelona Institute for Global Health (ISGlobal) sheds light on public trust in COVID-19 vaccine science and its impact on vaccine acceptance in the United States from 2021 to 2023.
A new study led by researchers at Albert Einstein College of Medicine involving more than 200,000 adults found that the COVID-19 pandemic caused a 29% increase in risk for developing dyslipidemia, a condition involving abnormal lipid (fat) levels in the blood. Seniors and people with type 2 diabetes were even more strongly affected, experiencing an approximately two-fold increased risk for developing dyslipidemia, which is a major risk factor for cardiovascular diseases such as heart attack and stroke. The research was published today in the print edition of The Journal of Clinical Investigation.